서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 31 of 31

Issue DateTitle / Author(s) / CitationFileAltmetrics
2013-05
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
DOI
2013-11
Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis
DOI
2013-11
Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis
DOI
2017-10
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
DOI
2018-05
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial
DOI
2018-07
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial
DOI
2019-03
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
DOI
2019-08
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia The Phase 2 RAINSTORM Randomized Clinical Trial
DOI
2020-06
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
DOI
2020-10
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
DOI
2021-02
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
DOI
2021-04
Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score ≥10
DOI
2021-06
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
DOI
2021-11
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
DOI
2022-01
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
DOI
2022-02
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
DOI
2022-08
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
DOI
2022-09
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel +/- Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
DOI
2023-02
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
DOI
2023-02
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
DOI
2023-02
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
view fileDOI
2023-03
Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
DOI
2023-05
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
DOI
2023-08
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
DOI
2023-10
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
DOI
2024
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary
DOI
2024-02
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
DOI
2024-05
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Kitagawa, Yuko; Matsuda, Satoru; Gotoda, Takuji; Kato, Ken; Wijnhoven, Bas; Lordick, Florian; Bhandari, Pradeep; Kawakubo, Hirofumi; Kodera, Yasuhiro; Terashima, Masanori; Muro, Kei; Takeuchi, Hiroya; Mansfield, Paul F.; Kurokawa, Yukinori; So, Jimmy; Monig, Stefan Paul; Shitara, Kohei; Rha, Sun Young; Janjigian, Yelena; Takahari, Daisuke; Chau, Ian; Sharma, Prateek; Ji, Jiafu; de Manzoni, Giovanni; Nilsson, Magnus; Kassab, Paulo; Hofstetter, Wayne L.; Smyth, Elizabeth Catherine; Lorenzen, Sylvie; Doki, Yuichiro; Law, Simon; Oh, Do-Youn; Ho, Khek Yu; Koike, Tomoyuki; Shen, Lin; van Hillegersberg, Richard; Kawakami, Hisato; Xu, Rui-Hua; Wainberg, Zev; Yahagi, Naohisa; Lee, Yeong Yeh; Singh, Rajvinder; Ryu, Min-Hee; Ishihara, Ryu; Xiao, Zili; Kusano, Chika; Grabsch, Heike Irmgard; Hara, Hiroki; Mukaisho, Ken-ichi; Makino, Tomoki; Kanda, Mitsuro; Booka, Eisuke; Suzuki, Sho; Hatta, Waku; Kato, Motohiko; Maekawa, Akira; Kawazoe, Akihito; Yamamoto, Shun; Nakayama, Izuma; Narita, Yukiya; Yang, Han-Kwang; Yoshida, Masahiro; Sano, Takeshi

Gastric Cancer, Vol.27 No.3, pp.401-425

DOI
2024-07
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
DOI
2024-11
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
DOI
2025-02
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer
DOI
1